You are here

Generic Equivalent of Ultracet Granted Final Approval by FDA

DETROIT, Dec. 19 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd., (AMEX:CPD) announced today that the US Food and Drug Administration (FDA) have granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Tramadol Hydrochloride with Acetaminophen Tablets.

Caraco's Tramadol Hydrochloride (HCl) with Acetaminophen Tablets is the generic equivalent of Ortho-McNeil Pharmaceutical Inc. brand product, Ultracet(R), which is indicated for the short-term (five days or less) management of acute pain.

"We are extremely pleased on receiving this approval and plan to launch this product to the market immediately," said Daniel H. Movens, Chief Executive Officer. "This approval brings our total product portfolio to 19 different products represented by 41 strengths."

Source: Caraco Pharmaceutical Laboratories

Recent Headlines

Up to 70% Greater Risk of Bacterial Infection, 48% Risk for Fungal Infection
Patients Had Improved Lung Function, Fewer Exacerbations
Particularly Serious: Antidepressants, Drugs for Parkinson’s and Epilepsy
Drug “Remarkably Effective” at Killing Range of Gram-Positive Bacteria
Most Women Undergoing Surgery for Suspected Cancer Do Not Have It
Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy
Record-High Number of Cases in France, Italy, Greece, Other Locations
Will Have a Longer Shelf Life Than Current, Expired Stockpile